Skip to Main Content

Paper Details

Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Neuro Oncol
31
2021
Depatux, Depatux-M, Depatux-M antibody, EGFR, EGFR-amplified heterotopic PDXs, GBM, GBM12, GBM46, PDX models, PDXs, brain tumor, depatuxizumab mafodotin, epidermal growth factor receptor, glioblastoma, heterotopic tumors, intracranial tumors, tumor, tumor tissues, tumors
Author NameAffiliation
Shulan TianMayo Clinic
Michael S ReganBrigham and Women's Hospital, Harvard Medical School
Caterina GianniniDepartment of Laboratory Medicine and Pathology Mayo Clinic
Caterina GianniniDepartment of Laboratory Medicine and Pathology Mayo Clinic
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School
Nathalie Y R AgarDana-Farber Cancer Institute
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School
Forest M WhiteMassachusetts Institute of Technology
Forest M WhiteDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Forest M WhiteCenter for Precision Cancer Medicine, Massachusetts Institute of Technology
Jann N SarkariaMayo Clinic
  • 1 - 11

Datasets

Release 1.2